首页> 美国卫生研究院文献>BMJ Open Gastroenterology >Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

【2h】

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

机译：索非布韦联合利巴韦林对亚洲慢性丙型肝炎基因型2的真实疗效：系统评价和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundSofosbuvir plus ribavirin (SOF+RBV) for 12 weeks is the standard treatment for chronic hepatitis C (CHC) genotype 2 (GT2) in most of Asia despite availability of new CHC medications. SOF-RBV real-world effectiveness has only been reported in small and/or single-centre studies. Our goal was to determine the real-world effectiveness of 12-week SOF+RBV therapy for CHC GT2 in Asia.

机译：背景Sofosbuvir联合利巴韦林（SOF + RBV）治疗12周是大多数亚洲地区慢性丙型肝炎（CHC）基因型2（GT2）的标准治疗方法，尽管已有新的CHC药物可供使用。仅在小型和/或单中心研究中报告了SOF-RBV实际效果。我们的目标是确定针对亚洲CHC GT2的12周SOF + RBV治疗的实际效果。

著录项

期刊名称 BMJ Open Gastroenterology
作者
Bin Wei; Fanpu Ji; Yee Hui Yeo; Eiichi Ogawa; Biyao Zou; Christopher D Stave; Shuangsuo Dang; Zongfang Li; Norihiro Furusyo; Ramsey C Cheung; Mindie H Nguyen;
展开▼
作者单位

展开▼
年(卷),期 2018(5),1
年度 2018
页码 e000207
总页数 10
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词
hepatitis C liver cirrhosis genotype adverse drug reactions;

机译：丙型肝炎;肝硬化;基因型;药物不良反应;

相似文献

外文文献
中文文献
专利

1. Real-world Effectiveness (RWE) of Sofosbuvir plus Ribavirin (SOF plus RBV) Chronic Hepatitis C Genotype 2 (CHC GT 2) in Asia: A Systemic Review and Meta-analysis of Pooled SVR12 [J] . Wei Bin, Ji Fanpu, Yeo Yee Hui, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Sofosbuvir Plus利巴韦林（SOF Plus RBV）慢性丙基肝炎（CHC GT 2）在亚洲的实际效力（RWE）：汇集SVR12的全身审查和荟萃分析
2. Real-world Effectiveness (RWE) and Adverse Events with Sofosbuvir plus Ribavirin (SOF plus RBV) Based Therapies in Chronic Hepatitis C Genotype 3 (CHC GT 3) Patients in Asia-A Systematic Review of 8 Studies and 3510 Patient [J] . Wei Bin, Ji Fanpu, Yeo Yee Hui, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：亚洲慢性丙基肝炎患者的基于慢性丙基肝炎患者的核心培训疗法（SOF Plus RBV）的实际效力（RWE）和不良事件 - 对8项研究的系统审查和3510名患者
3. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis [J] . William Stokes, Carol Fenton, Fiona Clement, Canadian journal of gastroenterology & hepatology. . 2017,第期

机译：Sofosbuvir和Leadipasvir与Sofosbuvir，Ledipasvir和利巴韦林患者的疗效和安全性，患有肝硬化的基因型1的疗效和安全性，患有肝硬化，并且在治疗之前失败：系统审查和荟萃分析
4. Studies of Therapy with Thymosin α 1 in Combination with Pegylated Interferon α2a and Ribavirin in Nonresponder Patients with Chronic Hepatitis C [C] . ROBERTO CAMERINI, ALESSIA CIANCIO, ALFONSO DE ROSA, International Symposiumn on Thymosins in Health and Disease; 20070321-24; Washington,DC(US) . 2007

机译：胸腺素α1联合聚乙二醇化干扰素α2a和利巴韦林治疗慢性丙型肝炎无反应者的研究
5. Ribavirin systemic and intracellular exposure and its role on viral response and anemia in chronic hepatitis c genotype 1 infection [D] . Wu, Liviawati Sutjandra. 2015

机译：利巴韦林全身和细胞内暴露及其在慢性丙型肝炎基因型1感染中对病毒反应和贫血的作用
6. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir Ledipasvir and Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis [O] . William Stokes, Carol Fenton, Fiona Clement, 2017

机译：Sofosbuvir和Ledipasvir对比SofosbuvirLedipasvir和Ribavirin治疗慢性丙型肝炎肝硬化且治疗失败的患者12周的疗效和安全性：系统评价和荟萃分析

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

摘要

著录项

相似文献

相关主题

期刊订阅